Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results?

OBJECTIVES: This study investigated the efficacy and safety of adding systemic (IV) bevacizumab (Bev) to hepatic arterial infusion (HAI) with floxuridine (FUDR)/dexamethasone (Dex) in unresectable primary liver cancer. METHODS: Patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepa...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Kemeny, Nancy E., Schwartz, Lawrence, Gönen, Mithat, Yopp, Adam, Gultekin, David, D’Angelica, Michael I., Fong, Yuman, Haviland, Dana, Gewirtz, Alexandra N., Allen, Peter, Jarnagin, William R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: S. Karger AG 2011
Aiheet:
Clinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3123741/
https://ncbi.nlm.nih.gov/pubmed/21677464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000324704
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia